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A signiﬁcant increase in the incidental detection of small renal tumors has been observed with the routine use of cross-sectional
abdominal imaging. However, the proportion of small renal tumors associated with multifocal RCC has yet to be established. Here
then, we report our experience with the treatment of multifocal RCC in which the primary tumor was ≤4cm. In our series of 1113
RCC patients, 5.4% (60/1113) had multifocal disease at the time of nephrectomy. Discordant histology was present in 17% (10/60)
of patients with multifocal RCC. Nephron sparing surgery was utilized more frequently in patients with solitary tumors. Overall,
cancer-speciﬁc, and distant metastasis-free survival appeared to be similar between multifocal and solitary tumors. These ﬁndings
are consistent with previous series which evaluated multifocal RCC with tumors>4cm. With the known incidence of multifocality
RCC, careful inspection of the entire renal unit should be performed when performing nephron sparing surgery.
Copyright © 2008 Paul L. Crispen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The routine use of cross-sectional abdominal imaging has
led to a signiﬁcant increase in the diagnosis of renal cell
carcinoma (RCC) [1, 2]. An estimated 51000 new cases of
cancer of the kidney and renal pelvis were diagnosed in
2007, with the vast majority representing RCC [3]. While
the preponderance of patients with sporadic RCC will have
solitary tumors, 4–20% of patients will have multifocal
RCC at the time of diagnosis [4–9]. This is in contrast
to patients with hereditary forms of RCC, such as von
Hippel-Lindau, Birt-Hogg-Dub´ e, and hereditary papillary
renal carcinoma, who typically have multifocal disease at
the time of presentation [10–12]. Whether a patient with
multifocalRCChassporadic orhereditarydisease,treatment
decisions are based on balancing the preservation of renal
function with oncologic eﬃcacy. This is especially true in
the case of small (≤4cm) renal tumors, which are often
amenable to nephron sparing surgery (NSS) [13, 14].
Although several previous series have reported on the
incidence of multifocality (Table 1), there are limited data
on the incidence and outcomes of patients with small
(≤4cm) sporadic multifocal RCC. Here then, we review our
experience with the management and outcomes of patients
with multifocal sporadic RCC in which the primary tumor
size was ≤4cm.
2. MATERIALS AND METHODS
We studied 1113 patients treated with radical nephrectomy
or NSS for sporadic, pNX/pN0, pM0 RCC ≤4.0cm between
1970and2004.Ofthese,1053(94.6%)patientshadasolitary,
unilateral RCC. The remaining 60 (5.4%) patients had uni-
lateral multifocal RCC. Patients with bilateral disease at time
of presentation were excluded from analysis. Clinical and
pathologic variables were compared between patients with
multifocal and solitary tumors. Clinical variables evaluated
included patient age, gender, symptoms at presentation,
ECOG performance status, and type of surgery. Pathologic
features evaluated included 2002 primary tumor classiﬁca-
tion,histologicsubtype,nucleargrade,presenceofhistologic
necrosis,andsarcomatoiddiﬀerentiation.Histologicsubtype
was assigned following the recommendations of the 1997
Union Internationale Contre le Cancer and American Joint
CommitteeonCancerworkshopontheclassiﬁcationofRCC
[15]. For the 60 patients with multifocal RCC, pathologic2 Advances in Urology
Table 1: Incidence of multifocal RCC in prior series. ccRCC = clear cell renal cell carcinoma; pRCC = papillary renal cell carcinoma; NA =
not available.
Author Year Total Patients Multifocal (%) Median Tumor
≤4cm(%)
Size (cm)
Richstone 2004 1071 57 (5.3) 5.0 16%
Dimarco 2004 2373 101 (4.3) 4.5 ccRCC NA
4.0 pRCC
Lang 2004 255 37 (14.5) NA 12.9%
Junker 2002 372 61 (16.4) NA NA
Karayiannis 2002 56 10 (17.8) 7.5 30%
Schlichter 2000 281 48 (17.1) NA NA
Baltaci 2000 103 22 (21.4) 7.5 24.1%
Wunderlich 1999 260 36 (13.9) NA NA
characteristics of the largest tumor were summarized, with
theexceptionofhistologicsubtype.Allpathologicspecimens
were reviewed by a single urologic pathologist. Patient
followup data are obtained and maintained through our
nephrectomy registry. Information on patients who do not
follow up at our institution is obtained by a registered nurse
via outside medical records, patient/physician correspon-
dence, or death certiﬁcates. Fewer than 3% of the patients
in the Nephrectomy Registry have been lost to follow up.
Clinical and pathologic features between the multifocal
and solitary groups were compared using Wilcoxon rank
sum, chi-square, and Fisher’s exact tests. Overall, cancer-
speciﬁc and distant metastases-free survivals were estimated
using the Kaplan-Meier method and overall survival was
compared between patient groups using the log-rank test.
All tests were two-sided and P-values less than .05 were
considered statistically signiﬁcant. Statistical analysis was
performed using SAS software (SAS Institute, Cary, NC,
USA).
3. RESULTS
Multifocal RCC was present in 5.4% (60/1113) of patients
with a primary tumor ≤ 4cm. Clinical and pathologic
features between patients with solitary and multifocal RCC
tumors ≤ 4.0cm are summarized in Table 2.M u l t i f o c a l
disease was suspected in only 27% (16/60) of patients based
on preoperative imaging. Median age at surgery for the
solitary patients was 64 years (mean 62.3; range 22–87)
compared with 67.5 years (mean 64.1; range 21–82) for
the multifocal patients (P = .147). Median tumor size for
the solitary patients was 3.0cm (mean 2.8; range 0.2–4.0)
compared with 2.9cm (mean 2.8; range 0.4–4.0) for the
multifocal patients (P = .631). A comparison of histologic
s u b t y p ei ss h o w ni nTable 3. Note that 10/60 (17%) of
the patients with multifocal RCC had multiple tumors of
diﬀerent histologic subtypes.
Among the 1053 patients with solitary RCC, 414 died
at a median of 7.7 years following surgery (range 1 day to
37.0 years), including 29 who died from RCC at a median
of 5.5 years following surgery (range 0.5–21.5). Among the
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years). Forty-four patients experienced distant metastases at
a median of 4.0 years following surgery (range 0.2–21.5).
Sixteen patients experienced a contralateral recurrence at a
median of 2.9 years following surgery (range 0.3–13.8).
Among the 60 patients with multifocal RCC, 23 died at
a median of 6.1 years following surgery (range 0.7–14.1),
including 4 who died from RCC at 1.0, 3.4, 5.7, and 9.5
years following surgery, respectively. Among the 37 patients
who were still alive at last followup, the median duration
of followup was 7.6 years (range 0.7–29.3). Three patients
experienced distant metastases at 0.8, 0.9 and 6.8 years
following surgery, respectively. Eight patients experienced a
contralateral recurrence at a median of 5.5 years following
surgery (range 0.6–8.1).
Overall survival rates (SE, number still at risk) at 5 and
10 years following surgery were 84.8% (1.2%, 691) and
68.4% (1.7%, 373), respectively, for patients with solitary
RCC compared with 84.0% (4.9%, 40) and 63.3% (7.5%,
17), respectively, for patients with multifocal RCC (P = .531;
Figure 1). Median overall survival for the two groups was
15.2 and 12.3 years, respectively.Paul L. Crispen et al. 3
Table 2: Clinical and pathologic features.
Solitary N = 1053 Multifocal N = 60
Feature N (%) P-value
Age at Surgery (years)
<65 554 (52.6) 23 (38.3) .031
≥65 499 (47.4) 37 (61.7)
Sex
Female 339 (32.2) 11 (18.3) .025
Male 714 (67.8) 49 (81.7)
Symptoms at presentation
Absent 582 (55.3) 39 (65.0) .140
Present 471 (44.7) 21 (35.0)
Constitutional symptoms at presentation
Absent 893 (84.8) 49 (81.7) .512
Present 160 (15.2) 11 (18.3)
ECOG Performance status (N = 903)
0 749 (88.4) 50 (89.3) .846
≥1 98 (11.6) 6 (10.7)
Type of Surgery
Open radical nephrectomy 532 (50.5) 41 (68.3) .007
Open nephron-sparing surgery 460 (43.7) 16 (26.7)
Laparoscopic radical nephrectomy 23 (2.2) 3 (5.0)
Laparoscopic nephron-sparing surgery 38 (3.6) 0
2002 Primary tumor classiﬁcation
pT1a 1020 (96.9) 59 (98.3) 1.00
pT3a 20 (1.9) 1 (1.7)
pT3b 11 (1.0) 0
pT3c 2 (0.2) 0
RCC Nuclear grade
1 147 (14.0) 6 (10.0) .672
2 673 (63.9) 40 (66.7)
3 221 (21.0) 14 (23.3)
4 12 (1.1) 0
Coagulative tumor necrosis
Absent 921 (87.5) 54 (90.0) .562
Present 132 (12.5) 6 (10.0)
Sarcomatoid Diﬀerentiation
Absent 1048 (99.5) 60 (100.0) 1.00
Present 5 (0.5) 0
Cancer-speciﬁc survival rates (SE, number still at risk)
at 5 and 10 years following surgery were 98.7% (0.4%, 691)
and96.7%(0.7%,373),respectively,forpatientswithsolitary
RCC compared with 96.2% (2.6%, 40) and 89.0% (5.7%,
17),respectively,forpatientswithmultifocalRCC(Figure 2).
Median cancer-speciﬁc survival was not attained for either
group during the observed duration of followup. Because
so few patients with multifocal RCC died from RCC, no
statistical comparison of outcome between the two patient
groups was performed.
Distant metastases-free survival rates (SE, number still
at risk) at 5 and 10 years following surgery were 97.6%
(0.5%, 687) and 95.1% (0.9%, 368), respectively, for patients
with solitary RCC compared with 96.5% (2.1%, 39) and
93.7% (3.7%, 17), respectively, for patients with multifocal
RCC (Figure 3). Median distant metastases-free survival was
not attained for either group during the observed duration
of followup. Because so few patients with multifocal RCC
experienced distant metastases, no statistical comparison of
outcome between the two patient groups was performed.
Contralateral recurrence-free survival rates (SE, number
still at risk) at 5 and 10 years following surgery were
99.1% (0.3%, 684) and 98.3% (0.5%, 366), respectively, for
patients with solitary RCC compared with 94.4% (3.2%,
38) and 79.2% (6.9%, 16), respectively, for patients with
multifocal RCC (P < .001; Figure 4). Median contralateral4 Advances in Urology
Table 3: RCC histologic subtype.
Patient Group N (%)
Solitary RCC (N = 1053)
Clear cell 771 (73.2)
Papillary 226 (21.5)
Chromophobe 45 (4.3)
Collecting duct 2 (0.2)
RCC, not otherwise speciﬁed 9 (0.9)
Multifocal RCC (N = 60)
Clear cell 26 (43.3)
Papillary 23 (38.3)
Chromophobe 1 (1.7)
Clear cell + papillary 8 (13.3)
Clear cell + chromophobe 1 (1.7)



































recurrence-free survival was not attained for either group
during the observed duration of followup.
4. DISCUSSION
In the current series of tumors ≤ 4cm, the rate of multifocal
RCC was similar to prior reports. In a review of series
published between 1988 to 1999, multifocal disease was
noted in 15.2% (179/1,180) of patients, with 9–100% of the
primary tumors being ≤ 4cm in individual reports [13].
Contemporary series have shown a similar rate of multifocal
RCC, ranging from 4.3% to 21.4% [4–9, 17, 18]. With
the known incidence of multifocal disease, the ability to
identify multifocal renal tumors preoperatively is extremely
important and has been evaluated by several series. Kletscher
etal.notedthatpreoperativeimagingsuggestedmultifocality
in only 44% (7/16) of patients prior to nephrectomy
[19]. While in the series by Richstone et al. only 33% of
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Figure 3: Distant metastasis-free survival in patients with multifo-
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Figure 4: Contralateral recurrence-free survival in patients with
multifocal versus solitary RCC.
resulting in the discovery of occult multifocal disease in
3.5% of all patients overall at the time of nephrectomy
[7]. Another series by Schlichter et al. investigated the
ability of ultrasound and computed tomography to identify
multifocality. Upon pathologic evaluation 17.1% (48/281) of
radical nephrectomy specimens contained multifocal RCC.
However, preoperative imaging was only able to identify
23% (11/48) of multifocal tumors. Collectively, these and
the current series demonstrate that preoperative imaging
is not a sensitive means of identifying multifocal disease
preoperatively. Thus complete mobilization and inspection
on the entire kidney is warranted when performing NSS to
properly evaluate the presence of multifocal disease.
Several associations have been suggested between clini-
copathologic features and the presence of multifocal RCC
including primary tumor size, histologic subtype, bilateral
disease, nodal status, and tumor stage. However, only two
series have performed multivariate analysis when evaluating
the associations between multifocality and clinicopathologicPaul L. Crispen et al. 5
Table 4: Cancer-speciﬁc survival in patients with multifocal versus solitary RCC. ccRCC = clear cell renal cell carcinoma; pRCC = papillary
r e n a lc e l lc a r c i n o m a ;N S= not signiﬁcant.
Author N multifocal 5 year survival N solitary 5 year survival P-value
Dimarco et al. [4]
40 (ccRCC) 74.6% 1934 (ccRCC) 69.0% .47
29 (pRCC) 100% 237(pRCC) 86.6% .62
Lang et al. [5] 37 74.0% 218 79.9% .26
Richstone et al. [7] 51 71.5%∗ 938 73.2%∗ NS
M´ ejean et al. [16] 28 (pRCC) 96% 30 (pRCC) 100% .53
∗ Disease-free survival.
features. Baltaci et al. evaluated 103 cases of RCC and noted
the incidence of multifocal RCCto be 21.4% [18].Univariate
and multiple logistic regression analysis demonstrated that
primary tumor stage was the only independent predictor of
multifocality. In the series by Richstone et al. of 1071 radical
nephrectomy specimens, 5.3% of patients were noted to have
multifocal RCC [7]. Multivariate analysis of this population
revealed signiﬁcant associations between multifocality with
papillary subtype, lymph node metastasis, advanced tumor
stage (pT4), and bilateral disease. Interestingly, neither
series noted a signiﬁcant association with tumor size and
multifocal RCC. This is important to consider when treating
small renal tumors, as size alone has not been shown to
predict the presence of multifocal disease.
Discordant pathology between the primary and satellite
tumors occurs in up to 6–30% of multifocal tumors [4,
7, 19]. A similar rate of discordant histology between the
primary and satellite tumors was noted in the current series
at 17%. Although it is obvious that separate events are likely
responsibleformultifocalRCCwithdiscordanthistology,the
origin of multifocal RCC with concordant histology is not
as apparent. However, the evaluation of genetic markers has
provided insight into the origin of multifocal RCC. An initial
report by Miyake et al. evaluated the loss of heterozygosity
(LOH) using 18 satellite markers in 10 patients with multi-
focal clear cell RCC (ccRCC) [20]. Identical LOH patterns
were noted in 80% (8/10) cases, suggesting that multifocal
ccRCC represent intrarenal metastasis. In a second report
examining the genetic clonality of multifocal ccRCC by
Junker et al. 89% (17/19) cases demonstrated identical LOH
patterns [17]. In contrast to ccRCC, multifocal papillary
RCC appears to represent independent primary tumors. In a
report by Jones et al. LOH was examined in 21 patients with
multifocalpapillaryRCC[21].Themajority,95%(20/21),of
cases demonstrated distinct LOH patterns between tumors
suggesting that multifocal papillary tumors do not represent
intrarenal metastasis, unlike ccRCC.
Survival outcomes following the treatment of multifocal
RCC have been evaluated in several series (Table 4). Dimarco
et al. reviewed 2373 patients treated for RCC over 30
years. Multifocal disease was present in 4.3% (101/2373)
of all patients. Of the patients with multifocal disease
70% (71/101) had multifocal lesions of the same histologic
subtype; these patients were utilized to evaluate survival
outcomes. Ipsilateral recurrence rates were similar between
multifocal and solitary RCC following radical nephrectomy.
Contralateral recurrence was more common in patients
with multifocal ccRCC with an increased risk ratio of 2.91;
however, this increase did not reach statistical signiﬁcance (P
= 1.42). However, in a separate report by Bani-Hani et al.
a signiﬁcant association between the risk of contralateral
recurrence and multifocality was demonstrated [22]. The
association between contralateral recurrence and multifocal-
ity was again noticed in current series which only includes
RCC ≤4cm. Cancer-speciﬁc survival was similar between
patients with multifocal RCC at 1, 5, and 10 years following
nephrectomy in patients with clear cell and papillary RCC
[23]. Similar ﬁndings were noted by Lang et al. in the review
of 255 patients undergoing radical nephrectomy [5]. In this
series multifocality waspresent in 14.5% (37/255) of patients
undergoing radical nephrectomy for RCC. Multifocality was
notassociatedwithmetastaticprogression,cancer-speciﬁcor
overall survival in patients treated with radical nephrectomy
duringmedianfollowupof183monthscomparedtopatients
treated for solitary tumors. Additionally, in the report by
Richstone et al. no signiﬁcant diﬀerence was noted in 5 year
disease-free (71.5% versus 73.2%) and overall (75.2% versus
79.3%) survival when comparing patients with multifocal
and solitary RCC [7]. In another study by M´ ejean et al.
focusingonpapillaryRCC,thepresenceofmultifocaldisease
was not a signiﬁcant predictor of overall survival compared
to solitary tumors [16]. Collectively these results, with the
inclusion of the results from the current series, suggest that
cancer speciﬁc outcomes are equivalent between patients
with multifocal and solitary RCC when treated with radical
nephrectomy.
NSS in the management of solitary RCC provides equiv-
alent oncologic eﬃcacy while improving overall survival
compared to radical nephrectomy [13, 24, 25]. Although
there are limited data on the eﬃcacy of NSS when treating
sporadic multifocal RCC, available data suggest that NSS
has equivalent oncologic eﬃcacy when treating multifocal
disease. An initial report from the Mayo Clinic by Blute
et al. reviewed 16 cases of multifocal tumors treated with
NSS [23]. 6/16 (38%) of these patients had a solitary kidney
at the time of presentation. Local recurrence was noted in
2/16 patients at 1.7 and 2.8 years following NSS. Recurrent
disease was treated with repeat NSS in one patient and
systemic therapy in the other. Cancer speciﬁc survival was
100% at 5 years, however 2/16 patients died of RCC at 6
and 11 years postoperatively. Because of the small number
of patients treated, survival outcome comparisons were
not made between patients treated with NSS and radical
nephrectomy.6 Advances in Urology
Additionally, when considering disease recurrence in
patients undergoing NSS for multifocal disease, it can be dif-
ﬁcult discriminating recurrent and persistent disease. Local
treatment failures in patients previously treated for multifo-
calRCCdoesnotautomaticallyindicateradicalnephrectomy
of the renal remnant. Two recent series have reported the
feasibility and outcomes of salvage partial nephrectomy in
patients with local recurrence following a previous partial
nephrectomy [26, 27]. Bratslavsky et al. reported on 11
patients undergoing salvage partial nephrectomies for von
Hippel-Lindau disease [27]. Three renal remnants were lost
whileattemptingtopreserverenalfunction,and46%ofcases
were associated with major postoperative complications. It
should be noted that salvage partial nephrectomy in this
series was deﬁned as at least the third partial nephrectomy
on the renal remnant. A second series by Magera et al.
reported outcomes following salvage partial nephrectomy
in 18 patients (8 solitary kidneys, 7 patients with von
Hippel-Lindau disease) [26]. Postoperative complications
were noted in 28% of patients. Although there was no
reported loss of a renal remnant in this series, chronic renal
insuﬃciency(serumcreatinine>2.0mg/dl)wasnotedinone
patientandchronicrenalfailure(serumcreatine>2.5mg/dl)
in two others. Obviously, salvage partial nephrectomy was
performed for absolute indications in all cases in an attempt
topreserverenalfunctionandavoidlong-termhemodialysis.
Additional data from series evaluating the eﬃcacy of
NSS for multifocal RCC in patients with von Hippel-Lindau
disease have demonstrated the signiﬁcant impact of tumor
size on future disease progression. In the series by Duﬀey
etal.,NSSwasutilizedin97%ofpatientswithtumors ≤3cm
compared to 69% in patients with tumors >3cm[14]. Pro-
gression to metastatic disease was noted in 27% of patients
treated for tumors >3cm (mean followup 73 months);
however,nopatientstreatedfortumors ≤3cmdemonstrated
disease progression (mean followup 58 months). Although
these data suggest that small multifocal RCCs can be treated
with NSS, with a low rate of progression to metastatic
disease, direct comparisons between the natural history of
sporadic and hereditary multifocal RCC should be made
with caution.
5. CONCLUSIONS
In the current series multifocal RCC was present in 5.4% of
patientswithtumors ≤4cm.MultifocalRCCpresentsseveral
challenges in terms of diagnosis and treatment. Although
multifocal disease is present in only a small proportion of
patients with RCC, recognition of multifocality is important
to ensure appropriate treatment. As preoperative imaging is
animperfectmeansofestablishingthepresenceofmultifocal
disease, careful intraoperative inspection of the entire renal
unit should be performed routinely during NSS. Based
on the current and other available series, the presence
of multifocal disease does not portend a worse prognosis
compared to solitary RCC. Additional evaluation of the role
of NSS in patients with multifocal sporadic RCC, especially
among those with tumors ≤4cm, is warranted.
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